Breaking News: XOMA Hits $5 Million Milestone with FDA Approval of Tovorafenib for Pediatric Low-Grade Glioma Treatment
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance…